Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 1,730 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $51,830.80. Following the completion of the transaction, the chief financial officer now owns 86,370 shares of the company’s stock, valued at approximately $2,587,645.20. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00.

Apellis Pharmaceuticals Trading Up 0.9 %

NASDAQ APLS opened at $30.39 on Thursday. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $3.78 billion, a P/E ratio of -14.97 and a beta of 0.94. The business has a fifty day simple moving average of $31.95 and a 200 day simple moving average of $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.17) earnings per share. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on APLS. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a research note on Tuesday, December 17th. Piper Sandler cut their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Mizuho lowered their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada restated a “sector perform” rating and set a $26.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday. Finally, Wells Fargo & Company dropped their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the 3rd quarter valued at $27,000. True Wealth Design LLC bought a new position in Apellis Pharmaceuticals during the third quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new stake in Apellis Pharmaceuticals during the third quarter worth about $56,000. KBC Group NV raised its position in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).